Angiogenin: A marker for preterm delivery in midtrimester amniotic fluid

C. Y. Spong, A. Ghidini, D. M. Sherer, J. C. Pezzullo, M. Ossandon, G. S. Eglinton

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

OBJECTIVE: Neovascularization is a response of tissue to ischemic damage. Placental ischemia is thought to underlie a significant portion of preterm deliveries. Our objective was to evaluate whether angiogenin, a potent inducer of neovascularization, is increased in midtrimester amniotic fluid of patients destined to be delivered preterm. STUDY DESIGN: We designed a case-control study of singleton gestations undergoing midtrimester amniocentesis for standard genetic indications. Inclusion criteria were (1) pregnancy outcome information available, (2) gestational age at amniocentesis 15 to 20 weeks, (3) no evidence of fetal structural or chromosomal anomalies, and (4) absence of conditions associated with preterm delivery. Amniotic fluid angiogenin levels were measured by immunoassay and normalized by natural log transformation for statistical analysis. RESULTS: Eleven patients with preterm deliveries were matched with 33 controls. Amniotic fluid angiogenin levels were significantly higher in patients with preterm deliveries compared with controls (median 30.1 ng/ml [range 13.6 to 71.0 ng/ml] vs 17.8 ng/ml [7.8 to 43.3 ng/ml], p = 0.002). Demographic data were not significantly different. The association between angiogenin levels and preterm delivery persisted after small-for-gestational-age neonates were excluded (p = 0.02). Receiver-operator characteristic curve analysis showed that an angiogenin level of 31.0 ng/ml was the optimal cutoff point for prediction of preterm delivery (sensitivity 45.5%, specificity 91.0%, p = 0.03, odds ratio 6.0). CONCLUSIONS: Midtrimester amniotic fluid angiogenin levels are elevated in patients with preterm delivery. This supports the theory that preexisting intrauterine ischemia and inflammation are important risk factors for preterm delivery and may be already present in the early midtrimester.

Original languageEnglish (US)
Pages (from-to)415-418
Number of pages4
JournalAmerican journal of obstetrics and gynecology
Volume176
Issue number2
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Second Pregnancy Trimester
Amniotic Fluid
Amniocentesis
Gestational Age
Ischemia
Pregnancy Outcome
Immunoassay
angiogenin
Case-Control Studies
Odds Ratio
Demography
Newborn Infant
Inflammation
Sensitivity and Specificity
Pregnancy

Keywords

  • amniotic fluid
  • angiogenin
  • Preterm delivery

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Angiogenin : A marker for preterm delivery in midtrimester amniotic fluid. / Spong, C. Y.; Ghidini, A.; Sherer, D. M.; Pezzullo, J. C.; Ossandon, M.; Eglinton, G. S.

In: American journal of obstetrics and gynecology, Vol. 176, No. 2, 01.01.1997, p. 415-418.

Research output: Contribution to journalArticle

Spong, C. Y. ; Ghidini, A. ; Sherer, D. M. ; Pezzullo, J. C. ; Ossandon, M. ; Eglinton, G. S. / Angiogenin : A marker for preterm delivery in midtrimester amniotic fluid. In: American journal of obstetrics and gynecology. 1997 ; Vol. 176, No. 2. pp. 415-418.
@article{1a70523a7f4847f89b5a5ed38a335f20,
title = "Angiogenin: A marker for preterm delivery in midtrimester amniotic fluid",
abstract = "OBJECTIVE: Neovascularization is a response of tissue to ischemic damage. Placental ischemia is thought to underlie a significant portion of preterm deliveries. Our objective was to evaluate whether angiogenin, a potent inducer of neovascularization, is increased in midtrimester amniotic fluid of patients destined to be delivered preterm. STUDY DESIGN: We designed a case-control study of singleton gestations undergoing midtrimester amniocentesis for standard genetic indications. Inclusion criteria were (1) pregnancy outcome information available, (2) gestational age at amniocentesis 15 to 20 weeks, (3) no evidence of fetal structural or chromosomal anomalies, and (4) absence of conditions associated with preterm delivery. Amniotic fluid angiogenin levels were measured by immunoassay and normalized by natural log transformation for statistical analysis. RESULTS: Eleven patients with preterm deliveries were matched with 33 controls. Amniotic fluid angiogenin levels were significantly higher in patients with preterm deliveries compared with controls (median 30.1 ng/ml [range 13.6 to 71.0 ng/ml] vs 17.8 ng/ml [7.8 to 43.3 ng/ml], p = 0.002). Demographic data were not significantly different. The association between angiogenin levels and preterm delivery persisted after small-for-gestational-age neonates were excluded (p = 0.02). Receiver-operator characteristic curve analysis showed that an angiogenin level of 31.0 ng/ml was the optimal cutoff point for prediction of preterm delivery (sensitivity 45.5{\%}, specificity 91.0{\%}, p = 0.03, odds ratio 6.0). CONCLUSIONS: Midtrimester amniotic fluid angiogenin levels are elevated in patients with preterm delivery. This supports the theory that preexisting intrauterine ischemia and inflammation are important risk factors for preterm delivery and may be already present in the early midtrimester.",
keywords = "amniotic fluid, angiogenin, Preterm delivery",
author = "Spong, {C. Y.} and A. Ghidini and Sherer, {D. M.} and Pezzullo, {J. C.} and M. Ossandon and Eglinton, {G. S.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0002-9378(97)70508-8",
language = "English (US)",
volume = "176",
pages = "415--418",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Angiogenin

T2 - A marker for preterm delivery in midtrimester amniotic fluid

AU - Spong, C. Y.

AU - Ghidini, A.

AU - Sherer, D. M.

AU - Pezzullo, J. C.

AU - Ossandon, M.

AU - Eglinton, G. S.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - OBJECTIVE: Neovascularization is a response of tissue to ischemic damage. Placental ischemia is thought to underlie a significant portion of preterm deliveries. Our objective was to evaluate whether angiogenin, a potent inducer of neovascularization, is increased in midtrimester amniotic fluid of patients destined to be delivered preterm. STUDY DESIGN: We designed a case-control study of singleton gestations undergoing midtrimester amniocentesis for standard genetic indications. Inclusion criteria were (1) pregnancy outcome information available, (2) gestational age at amniocentesis 15 to 20 weeks, (3) no evidence of fetal structural or chromosomal anomalies, and (4) absence of conditions associated with preterm delivery. Amniotic fluid angiogenin levels were measured by immunoassay and normalized by natural log transformation for statistical analysis. RESULTS: Eleven patients with preterm deliveries were matched with 33 controls. Amniotic fluid angiogenin levels were significantly higher in patients with preterm deliveries compared with controls (median 30.1 ng/ml [range 13.6 to 71.0 ng/ml] vs 17.8 ng/ml [7.8 to 43.3 ng/ml], p = 0.002). Demographic data were not significantly different. The association between angiogenin levels and preterm delivery persisted after small-for-gestational-age neonates were excluded (p = 0.02). Receiver-operator characteristic curve analysis showed that an angiogenin level of 31.0 ng/ml was the optimal cutoff point for prediction of preterm delivery (sensitivity 45.5%, specificity 91.0%, p = 0.03, odds ratio 6.0). CONCLUSIONS: Midtrimester amniotic fluid angiogenin levels are elevated in patients with preterm delivery. This supports the theory that preexisting intrauterine ischemia and inflammation are important risk factors for preterm delivery and may be already present in the early midtrimester.

AB - OBJECTIVE: Neovascularization is a response of tissue to ischemic damage. Placental ischemia is thought to underlie a significant portion of preterm deliveries. Our objective was to evaluate whether angiogenin, a potent inducer of neovascularization, is increased in midtrimester amniotic fluid of patients destined to be delivered preterm. STUDY DESIGN: We designed a case-control study of singleton gestations undergoing midtrimester amniocentesis for standard genetic indications. Inclusion criteria were (1) pregnancy outcome information available, (2) gestational age at amniocentesis 15 to 20 weeks, (3) no evidence of fetal structural or chromosomal anomalies, and (4) absence of conditions associated with preterm delivery. Amniotic fluid angiogenin levels were measured by immunoassay and normalized by natural log transformation for statistical analysis. RESULTS: Eleven patients with preterm deliveries were matched with 33 controls. Amniotic fluid angiogenin levels were significantly higher in patients with preterm deliveries compared with controls (median 30.1 ng/ml [range 13.6 to 71.0 ng/ml] vs 17.8 ng/ml [7.8 to 43.3 ng/ml], p = 0.002). Demographic data were not significantly different. The association between angiogenin levels and preterm delivery persisted after small-for-gestational-age neonates were excluded (p = 0.02). Receiver-operator characteristic curve analysis showed that an angiogenin level of 31.0 ng/ml was the optimal cutoff point for prediction of preterm delivery (sensitivity 45.5%, specificity 91.0%, p = 0.03, odds ratio 6.0). CONCLUSIONS: Midtrimester amniotic fluid angiogenin levels are elevated in patients with preterm delivery. This supports the theory that preexisting intrauterine ischemia and inflammation are important risk factors for preterm delivery and may be already present in the early midtrimester.

KW - amniotic fluid

KW - angiogenin

KW - Preterm delivery

UR - http://www.scopus.com/inward/record.url?scp=0031027759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031027759&partnerID=8YFLogxK

U2 - 10.1016/S0002-9378(97)70508-8

DO - 10.1016/S0002-9378(97)70508-8

M3 - Article

C2 - 9065191

AN - SCOPUS:0031027759

VL - 176

SP - 415

EP - 418

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 2

ER -